NASDAQ
MDCX
Last Price
US $0.36
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Medicus Pharma Ltd. Common Stock cash flow to debt ratio of -570.04% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Medicus Pharma Ltd. Common Stock's free cash flow has decreased 122.27% from $-10.25M last year to $-22.78M, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
Medicus Pharma Ltd. Common Stock's debt to equity ratio is 0.13, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial risk - Healthy debt to equity ratio development.
Medicus Pharma Ltd. Common Stock's debt has increased relative to shareholder equity from 0.10 last year to 0.13 today, signaling weakened financials
Financial risk - Net debt/EBITDA.
Medicus Pharma Ltd. Common Stock has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
Medicus Pharma Ltd. Common Stock's interest coverage ratio of 198.27 indicates that earnings with good margin can cover interest payments on company debt
Financial risk - Profit margin growth.
Medicus Pharma Ltd. Common Stock has insufficient data to evaluate this check.
Financial risk - Short term assets vs short term liabilities.
Medicus Pharma Ltd. Common Stock's short-term liabilities of $9.94M exceed its short-term assets of $9.89M, signaling financial risk
Decreasing performance - ROA.
Medicus Pharma Ltd. Common Stock's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Medicus Pharma Ltd. Common Stock's return on equity of -4.09K%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Medicus Pharma Ltd. Common Stock's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Medicus Pharma Ltd. Common Stock had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Medicus Pharma Ltd. Common Stock has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Medicus Pharma Ltd. Common Stock has negative free cash flow, indicating cash burn
Decreasing performance - Healthy earnings growth.
Medicus Pharma Ltd. Common Stock's yearly earnings has decreased 127.39% since last year from $-11.16M to $-25.37M, signaling decreasing performance
Increasing performance - Healthy revenue growth.
Medicus Pharma Ltd. Common Stock's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance
Decreasing performance - ROIC.
ROIC -2.19K% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
Medicus Pharma Ltd. Common Stock has insufficient revenue history to calculate 3-year revenue CAGR.
Increasing performance - Revenue consistency.
Medicus Pharma Ltd. Common Stock had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Medicus Pharma Ltd. Common Stock had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Medicus Pharma Ltd. Common Stock has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Medicus Pharma Ltd. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Medicus Pharma Ltd. Common Stock is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Medicus Pharma Ltd. Common Stock has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Medicus Pharma Ltd. Common Stock has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - P/B ratio.
Medicus Pharma Ltd. Common Stock has negative shareholder equity; price-to-book is not meaningful and the check fails
Overvalued - P/S ratio.
Medicus Pharma Ltd. Common Stock has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-4086.31%
Return on equity
ROIC: -2193.34%
Valuation History
-0.19X
Price to Earnings
EV/EBITDA: -0.08X
Cash flow
Profit margin
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Fair Value
Market $0.36
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.